CERo Therapeutics Holdings - Bathi resik saben saham sajrone 12 wulan pungkasan CERO

By adhering to ethical testing standards and environmental waste disposal, CERo Therapeutics minimizes risks. The GURU.Markets portal provides this chart, where the annual net income per share TTM dynamics illustrate the current trend, and the value captures this metric. The company's revenues are based on innovations in cell therapy, while an intensive R&D pipeline featuring T-Chime technology ensures a technological breakthrough.
Rincian metrik keuangan lan pasar CERo Therapeutics Holdings (CERO)

Year-over-year (YoY) EPS growth (TTM) measures the percentage change in net income per share over a rolling twelve-month period. Investors analyze current EPS YoY TTM momentum to identify hidden fundamental trends between quarterly reports. This metric reflects the efficiency of profit capitalization. For CERo Therapeutics (CERO), this indicator is secondary, as biotech success depends on clinical trials rather than economic cycles. Profit dynamics here only indirectly indicate the cost of attracting R&D financing.